Innovation / 12.05.2022
Eckert & Ziegler with Sales Growth in the First Quarter of 2022
Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, TecDAX) increased its sales by 13% to EUR 49.9 million in the first quarter of 2022. The net profit of EUR 6.7 million or EUR 0.32 per share was below the previous year's quarter. This earnings gap compared to the previous year is due to a one-off effect of around EUR 6.8 million in the first quarter of 2021, in which the Group sold its tumour irradiation business at a profit. Despite the pandemic and the war in Ukraine, the Q1 figures reflect a stable start to the year.
Revenue in the Medical segment was EUR 20.1 million in the first quarter, EUR 1.2 million or 5% below the previous year's figure. Taking into account the loss of sales of EUR 1.1 million due to the deconsolidation of the tumour irradiation business, the sales level was maintained compared to the previous year.
The Isotope Products segment achieved revenue of EUR 29.8 million, which is EUR 7.0 million or about 31% higher than in the first three months of 2021, due to rising oil and gas prices and an associated exceptional demand in radiometric components for energy companies. Around EUR 1.9 million of the increase is attributable to the acquisition of the Argentinian company Tecnonuclear SA in January 2022.
The results of the first quarter of 2022 are in line with the expectations of the Executive Board. The forecast for the 2022 financial year published in March remains unaffected. The Executive Board continues to expect sales of around EUR 200 million and a net profit of around EUR 38 million. The forecast is subject to the assumption that the developments in Ukraine do not result in any major disruptions.
The complete quarterly report can be viewed here: https://www.ezag.com/fileadmin/user_upload/ezag/investors-financial-reports/englisch/euz122e.pdf
About Eckert & Ziegler.
Eckert & Ziegler Strahlen- und Medizintechnik AG with more than 900 employees is a leading specialist for isotope-related components in nuclear medicine and radiation therapy. The company offers a broad range of services and products for the radiopharmaceutical industry, from early development work to contract manufacturing and distribution. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche Börse.
News Buch Berlin
A fine-tuned gene editor
The molecular tool CRISPR-Cas9 can be used to treat inherited blood disorders, but this may cause unintended genetic alterations. A team led by MDC researchers Klaus Rajewsky and Van Trung Chu has now...more ...
What makes blood vessels grow?
Blood vessels must adapt their growth to the nutrients available in their surroundings so that they can keep organs adequately supplied. A team led by Michael Potente has identified two proteins that ...more ...
Maike Sander named to lead the Max Delbrück Center
Maike Sander has been selected to direct the Max Delbrück Center for Molecular Medicine (MDC). The Supervisory Board appointed the diabetes researcher and professor of pediatrics and cellular and mole...more ...
Events Buch Berlin
Robotik-Aktionstag in der Stadtteilbibliothek Buch
Was hat Robotik im Alltag eigentlich mit uns zu tun? Experimente zum Mitmachen und Roboter zum Ausprobieren!more ...
Lange Nacht der Wissenschaften auf dem Campus Berlin-Buch und am MDC in Mitte
Wer das Leben verstehen will, sollte sich auch auf die Welt der Moleküle einlassen. Dass das nicht nur für Experten interessant ist, zeigt das Programm des Campus Berlin-Buch/MDC-Mitte während der Lan...more ...
Buch_KulTour: Bucher Aktionswoche zum geplanten Bildungs- und Integrationszentrum (BIZ)
Bucher Akteure bieten vom 6. bis 10. Juli 2022 zahlreiche Veranstaltungen als Vorschauf auf das BIZ an. Das Gläserne Labor ist mit Mitmach-Experimenten nicht nur für Kinder mit dabei.more ...